Q3 2025 Legend Biotech Corp Earnings Call Transcript
Key Points
- CARVYKTI net trade sales reached approximately $524 million, marking an 84% increase year-over-year.
- Legend Biotech Corp (LEGN) has treated over 9,000 patients with CARVYKTI, making it the strongest CAR-T launch to date.
- The FDA approved an update to include CARVYKTI's overall survival benefit in its label, enhancing its profile.
- Legend Biotech Corp (LEGN) is expanding its manufacturing capacity, with the Tech Lane facility initiating commercial production.
- The company maintains a strong cash position of nearly $1 billion, supporting its growth and innovation strategies.
- Legend Biotech Corp (LEGN) reported a net loss of $40 million for the third quarter.
- The company faces challenges in achieving profitability, with expectations set for 2026.
- There is a need for effective bridging therapy to manage high tumor burden and mitigate adverse events.
- The company is transitioning from a supply-constrained to a demand-constrained environment, requiring strategic demand mobilization.
- Despite strong sales growth, there is slower-than-anticipated growth in earlier line settings for CARVYKTI.
Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech's third quarter 2025 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would like now to turn the conference over to Jessie Yeung, Vice President of Investor Relations and Finance. Please go ahead.
Good morning. This is Jessie Yeung, Vice President of Investor Relations and Finance at Legend Biotech. Thank you for joining our conference call today to review our third quarter of 2025 performance. Prior to this call, we issued a press release announcing our financing results for the quarter. You can find the press release on our IR website at legendbiotech.com.
Joining me on today's call are Ying Huang, the company's Chief Executive Officer; Alan Bash, the company's President of CARVYKTI; and Carlos Santos, the company's Chief Financial Officer. Following the prepared remarks, we will open up the call for Q&A. We have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
